| Hepatoprotective effects of geniposide in a rat model of nonalcoholic steatohepatitis. | |
| | |
MedLine Citation:
|
PMID: 21401612 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: Nonalcoholic steatohepatitis (NASH), a metabolic disorder of the liver, may gradually evolve into fibrosis or cirrhosis. Recent studies have suggested that geniposide can effectively inhibit experimental liver fibrosis. Therefore, the aim of this study was to determine whether geniposide can influence the early phase of fibrogenesis in an animal model of NASH. METHODS: Male Sprague-Dawley rats were given a high fat diet alone or the same diet combined with geniposide at doses of 25, 50 or 100 mg/kg for six weeks. Ten rats received corresponding solvent as a normal control. KEY FINDINGS: Treatment with geniposide could improve liver histology through reducing the elevated liver index (liver weight/body weight), serum alanine aminotransferase and aspartate aminotransferase. Total cholesterol, triglycerides and free fatty acids in serum and liver decreased in geniposide-treated rats. Furthermore, geniposide increased serum insulin levels but reduced serum tumour necrosis factor-α level in high-fat diet rats. In addition, geniposide suppressed expression of CYP2E1 and increased peroxisome proliferator-activated receptor-α (PPARα) expression. These benefits may be associated with increased superoxide dismutase and decreased malondialdehyde in liver. CONCLUSIONS: Geniposide exerts protective effects against hepatic steatosis in rats fed with a high fat diet; the underlying mechanism may be associated with its antioxidant actions or regulation of adipocytokine release and expression of PPARα. |
| | |
Authors:
|
Taotao Ma; Cheng Huang; Guojun Zong; Dajun Zha; Xiaoming Meng; Jun Li; Wenjian Tang |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2011-03-03 |
Journal Detail:
|
Title: The Journal of pharmacy and pharmacology Volume: 63 ISSN: 2042-7158 ISO Abbreviation: J. Pharm. Pharmacol. Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-03-15 Completed Date: 2011-07-19 Revised Date: 2011-09-13 |
Medline Journal Info:
|
Nlm Unique ID: 0376363 Medline TA: J Pharm Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 587-93 Citation Subset: IM |
Copyright Information:
|
© 2011 The Authors. JPP © 2011 Royal Pharmaceutical Society. |
Affiliation:
|
Department of Pharmacy, Anhui Medical University, Hefei bHefei XinFeng Co. Ltd, Hefei, Anhui 230032, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alanine Transaminase
/
blood Animals Anti-Inflammatory Agents / pharmacology*, therapeutic use* Aspartate Aminotransferases / blood Cytochrome P-450 CYP2E1 / biosynthesis Dietary Fats / adverse effects Disease Models, Animal Dose-Response Relationship, Drug Drug Evaluation, Preclinical Fatty Liver / etiology, metabolism, prevention & control Insulin / blood Iridoids / pharmacology*, therapeutic use* Lipid Metabolism / drug effects Male Malondialdehyde / metabolism PPAR alpha / biosynthesis Rats Rats, Sprague-Dawley Superoxide Dismutase / metabolism Tumor Necrosis Factor-alpha / blood |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Dietary Fats; 0/Iridoids; 0/PPAR alpha; 0/Tumor Necrosis Factor-alpha; 11061-68-0/Insulin; 24512-63-8/geniposide; 542-78-9/Malondialdehyde; EC 1.14.14.1/Cytochrome P-450 CYP2E1; EC 1.15.1.1/Superoxide Dismutase; EC 2.6.1.1/Aspartate Aminotransferases; EC 2.6.1.2/Alanine Transaminase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antimicrobial activity and chemical composition of the essential oil of Hofmeisteria schaffneri.
Next Document: Antihyperalgesic activity of verbascoside in two models of neuropathic pain.